PT Tempo Scan Pacific Tbk.

Pharmaceuticals

Head Office Tempo Scan Pacific Tower 16th Floor Summary of Financial Statement
Jl. HR. Rasuna Said Kav. 3-4, Jakarta 12950
Phone (021) 2921-8888 (Million Rupiah)
Fax (021) 2920-9999 2011 2012 2013
Email: investorrelation@thetempogroup.com
Total Assets 4,250,374 4,632,985 5,407,958
Website: www.thetempogroup.com
Current Assets 3,121,980 3,393,778 3,991,116
Factories - EJIP Industrial Park Plot I G
of which
Lemahabang, Bekasi 17550
Cash and cash equivalents 1,608,819 1,651,451 1,792,222
Phone (021) 897-1553, 897-5173
Trade receivables 599,337 745,771 808,788
Fax (021) 897-1563
Inventories 726,343 764,579 1,000,694
- EJIP Industrial Park Plot I H
Non-Current Assets 1,128,395 1,239,207 1,416,842
Lemahabang, Bekasi 17550 of which
Phone (021) 897-0801, 897-0802 Fixed Assets-Net 886,135 1,000,822 1,203,852
Fax (021) 897-0764 Deffered Tax Assets-Net 36,605 40,322 36,028
Business Pharmaceuticals Investments 20,101 18,550 15,767
Company Status PMDN Other Assets 154,922 137,792 136,605

Financial Performance: The Company booked net income Liabilities 1,204,439 1,279,829 1,545,006
amounted IDR674 billion in 2013, higher than last year income Current Liabilities 1,046,406 1,097,135 1,347,466
worth IDR643 billion. of which
Brief History: TSP has been a certified GMP pharmaceu- Bank loans 139,740 93,838 184,500
Trade payables 574,346 628,807 745,323
tical manufacturer since 1990 with certification for 11 kinds of
Taxes payable 43,704 56,703 34,136
dosage forms. To date, the company has already produced and Non-Current Liabilities 158,032 182,694 197,540
marketed 105 items for distribution domestically and 43 items
for export. Shareholders' Equity 3,045,935 3,353,156 3,862,952
TSPs production activities are carried out at its 11,622 Paid-up capital 225,000 225,000 225,000
Paid-up capital
sq metres plant in Cawang, East Jakarta. Its factory was recently
in excess of par value 124,457 124,457 397,349
upgraded and it has a work force of 945. Revaluation of fixed assets n.a n.a n.a
Tablet capacity is by far the largest compared to the cap- Retained earnings 2,696,478 3,003,699 3,240,603
sule and liquid lines. The table line is currently running at 90%
utilisation based on one extended shift per day. The table capac- Net Sales 5,780,664 6,630,810 6,854,889
Cost of Goods Sold 3,580,621 4,142,489 4,135,087
ity is primarily devoted to the production of the Bode lines. Gross Profit 2,200,043 2,488,321 2,719,803
Total tablet production is approximately two billion units Operating Expenses 1,542,254 1,786,514 2,071,818
per year, while capsules are around 110 million units and liquid, Operating Profit 657,788 701,807 647,985
38 billion bottles. Other Income (Expenses) 82,312 110,573 181,951
Profit (loss) before Taxes 740,100 812,380 829,935
The majority of its capsule machinery is for the produc-
Comprehensive Profit (loss) 585,309 643,568 674,147
tion of Hemaviton. TSPs strength lies in its OTC products with
major brands Brodex, Brodexin, and Hemaviton, collectively, Per Share Data (Rp)
contributing approximately 70% of the consolidated pharma- Earnings per Share 130 143 150
ceutical revenue. Equity per Share 677 745 858
Dividend per Share 75 75 75
These products reportedly generate very high gross mar-
Closing Price 2,550 3,725 3,250
gins estimated to be around 60%. Neo-Rheumacyl the largest
single product contributor to the ethical product line, contrib- Financial Ratios
ute around 16% of the consolidated pharmaceutical revenue. PER (x) 19.61 26.05 21.69
Advertising and promotional activities are very important for PBV (x) 3.77 5.00 3.79
Dividend Payout (%) 0.58 0.52 n.a
successfully marketing OTC products and maintaining brand Dividend Yield (%) 0.03 0.02 n.a
royalty. TSP allocates approximately 20% of its OTC revenue
for this purpose. Although the percentage may seem slightly Current Ratio (x) 2.98 3.09 2.96
lower than those of its competitors, this is because most of its Debt to Equity (x) 0.40 0.38 0.40
Leverage Ratio (x) 0.28 0.28 0.29
OTC products are already very well known in Indonesia.
Gross Profit Margin (x) 0.38 0.38 0.40
Operating Profit Margin (x) 0.11 0.11 0.09
Net Profit Margin (x) 0.10 0.10 0.10
Inventory Turnover (x) 4.93 5.42 4.13
Total Assets Turnover (x) 1.36 1.43 1.27
ROI (%) 13.77 13.89 12.47
ROE (%) 19.22 19.19 17.45

Shareholders PER = 13,76x ; PBV = 2,89x (June 2014)

PT Bogamulia Nagadi 77.34% Financial Year: December 31
Public Accountant: Tanubrata Sutanto Fahmi & Rekan
Public 22.66%

498 Indonesian Capital Market Directory 2014

PT Tempo Scan Pacific Tbk. Pharmaceuticals

Board of Commissioners Board of Directors

President Commissioner Dian Paramita Tamzil
Commissioners Kustantinah, Olga Asihjati Adjiputro Wijaya,
Julian Aldrin Pasha
President Director Handojo Selamet Muljadi
Vice President Directors Diana Wirawan, Dewi Murni Sukahar
Directors Dondi Sapto Margono, Liza Prasodjo,
Irawati Sutanto, Phillips Gunawan, Hartaty Susanto,
Aviaska Diah Respati Herlambang
Suryadi Nagawiguna, Johanes Ivan Pradjanata

Number of Employees 5,900

No Type of Listing Listing Date Trading Date Number of Shares Total Listed
per Listing Shares

1 First Issue 17-Jun-94 17-Jun-94 17,500,000 17,500,000

2 Company Listing 17-Jun-94 24-Jan-95 57,500,000 75,000,000
3 Stock Split 13-Nov-95 13-Nov-95 75,000,000 150,000,000
4 Right Issue 09-Feb-98 09-Feb-98 300,000,000 450,000,000
5 Stock Split 14-Sep-06 14-Sep-06 4,050,000,000 4,500,000,000

Underwriter
PT DBS Securities

Stock Price, Frequency, Trading Days, Number and Value of Shares Traded and Market Capitalization
Stock Price Shares Traded Trading Listed Market
Month High Low Close Volume Value Frequency Day Shares Capitalization
(Rp) (Rp) (Rp) (Thousand Shares) (Rp Million) (Rp Million)
January-13 3,725 3,425 3,550 28,269.00 99,577.00 1,206 21 4,500,000,000 15,975,000.00
February-13 3,550 3,100 3,225 24,084.00 79,779.00 1,310 20 4,500,000,000 14,512,500.00
March-13 3,850 3,000 3,850 47,156.00 151,844.00 2,644 19 4,500,000,000 17,325,000.00
April-13 3,850 3,250 3,400 43,238.00 151,395.00 1,783 22 4,500,000,000 15,300,000.00
May-13 4,950 3,325 4,750 199,513.00 771,890.00 4,855 22 4,500,000,000 21,375,000.00
June-13 4,600 3,750 4,150 45,968.00 196,364.00 2,780 19 4,500,000,000 18,675,000.00
July-13 4,225 3,550 4,100 12,851.00 50,922.00 1,400 23 4,500,000,000 18,450,000.00
August-13 4,025 3,250 3,650 8,105.00 29,405.00 1,046 17 4,500,000,000 16,425,000.00
September-13 3,800 3,050 3,800 10,187.00 33,552.00 2,580 21 4,500,000,000 17,100,000.00
October-13 3,900 3,550 3,900 34,784.00 119,516.00 1,723 21 4,500,000,000 17,550,000.00
November-13 3,800 2,850 3,325 39,277.00 129,023.00 4,529 20 4,500,000,000 14,962,500.00
December-13 3,375 3,050 3,250 32,081.00 100,510.00 1,630 19 4,500,000,000 14,625,000.00
January-14 3,200 2,850 2,900 13,733.00 41,168.00 4,496 20 4,500,000,000 13,050,000.00
February-14 3,370 2,745 3,340 41,227.00 124,974.00 5,004 20 4,500,000,000 15,030,000.00
March-14 3,450 3,020 3,170 29,825.00 95,043.00 3,689 20 4,500,000,000 14,265,000.00
April-14 3,250 2,865 2,900 34,939.00 103,130.00 5,803 20 4,500,000,000 13,050,000.00
May-14 2,900 2,700 2,770 53,608.00 152,574.00 5,306 18 4,500,000,000 12,465,000.00
June-14 3,015 2,710 3,000 48,222.00 141,984.00 3,148 21 4,500,000,000 13,500,000.00

Stock Price and Traded Chart

Stock Price (Rp) Thousand Shares
5,000 10,000

4,500 9,000

4,000 8,000

3,500 7,000

3,000 6,000

2,500 5,000

2,000 4,000

1,500 3,000

1,000 2,000

500 1,000

- -
Jan-13 Mar-13 May-13 Jul-13 Sep-13 Nov-13 Jan-14 Mar-14 May-14

Institute for Economic and Financial Research 499